Nicolas B.
- Country
- France
- Department
- Internal Medicine
Research Overview
- HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial. CAESAR
- Efficacy of Certolizumab Pegol in Adult Women with Unexplained Recurrent Implantation Failure: A Double-Blind, Randomized, Placebo-Controlled Trial
- Evaluation of Rapcabtagene Autoleucel Versus Standard of Care in Systemic Lupus Erythematosus Patients with Active, Refractory Lupus Nephritis
Data & Insights
Has run more than one trial at 14 of 96 partner sites.
Specializations
Reproductive Medicine
The investigator specializes in treating recurrent implantation failure (RIF) in adult women, with particular focus on developing innovative therapeutic approaches using certolizumab for unexplained cases.
- Female Infertility Treatment
- Implantation Failure Management
- Reproductive Immunology
Research interests include immunological aspects of implantation and pregnancy outcomes.
Autoimmune Disorders
The investigator focuses on treating systemic lupus erythematosus (SLE), conducting research with novel therapies including belimumab and rapcabtagene autoleucel, particularly for patients with lupus nephritis.
- Early SLE Intervention
- Lupus Nephritis Treatment
- Innovative Cell Therapies
Special attention is given to kidney manifestations of lupus and targeted therapeutic approaches.
Inflammatory Conditions
The investigator examines treatments for extra-pulmonary sarcoidosis, exploring the therapeutic potential of hydroxychloroquine as a steroid-sparing agent in systemic treatment protocols.
- Sarcoidosis Management
- Steroid-Sparing Strategies
- Systemic Treatment Approaches
Research encompasses non-severe manifestations of sarcoidosis requiring systemic intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.